First, p300 regulates multiple pro-fibrotic genes related to the EndMT, angiogenesis, and inflammation, and p300 may therefore be a plausible target for treating fibrotic disease in CKD patients (Ruiz-Ortega et al, 2022). The gene discussed is EP300; the disease is chronic kidney disease.